SCHEMBL7148523

SCHEMBL7148523

CN(C(=O)CC(N)=O)c1ccc(COC(C)(C)C)cc1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PPIB P23284 2/20 0.38
GPR88 Q9GZN0 1/20 0.37
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 2/20 0.37
HPGD P15428 2/20 0.37
NPC1 O15118 1/20 0.37
GAA P10253 1/20 0.37
TSHR P16473 1/20 0.37
MAPK1 P28482 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
HSD17B10 Q99714 1/20 0.37
NOTUM Q6P988 1/20 0.35
NR1H4 Q96RI1 1/20 0.35
RET P07949 2/20 0.34
TRPV1 Q8NER1 1/20 0.33
MAPT P10636 1/20 0.33
POLQ O75417 1/20 0.33
MLYCD O95822 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7151472 0.84 PPIB (0.42) PPIBKDM4EALDH1A1HPGDNPC1
SCHEMBL7148527 0.83 PPIB (0.40) PPIBGPR88KDM4EALDH1A1HPGD
SCHEMBL7148520 0.80 PPIB (0.38) PPIBGPR88KDM4EALDH1A1HPGD
SCHEMBL7141049 0.79 CA1 (0.40) PPIBALDH1A1NR1H4POLQMLYCD
SCHEMBL10272760 0.73 POLQ (0.49) KDM4EALDH1A1GAAHSD17B10MAPT
SCHEMBL7092205 0.73 ALDH1A1 (0.45) KDM4EALDH1A1NPC1TSHRSMN1; SMN2
SCHEMBL4593319 0.73 KMT2A (0.51) PPIBALDH1A1POLQ
SCHEMBL18213828 0.72 PARP10 (0.58) ALDH1A1NPC1NR1H4TRPV1
SCHEMBL12011153 0.70 ESR1 (0.43) PPIBALDH1A1NPC1NOTUMNR1H4
SCHEMBL648537 0.70 AGXT (0.39) TSHRTRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1303485-A1 PYRROLIDINE DERIVATIVES AS INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME F. HOFFMANN-LA ROCHE AG (CH) 2003-04-23 EP disclosed
US-6541638-B2 (2S,4S)-1-(4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carbonyl)-piperidine-4-carboxylic acid ethyl ester for example; zinc protease inhibitors; for treating diseases associated with vasoconstriction HOFFMAN-LA ROCHE INC. 2003-04-01 US disclosed
US-20020049243-A1 Pyrrolidine derivatives HOFFMANN-LA ROCHE INC. 2002-04-25 US disclosed
WO-2002006222-A1 PYRROLIDINE DERIVATIVES AS INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME F. HOFFMANN-LA ROCHE AG (CH) 2002-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049243-A1 Pyrrolidine derivatives PREP, PEPD, DNPEP PPIB 304/4885GPR88 3826/4885KDM4E 1295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.